艾沙佐米、泊马度胺和地塞米松口服方案治疗复发/难治性多发性骨髓瘤的I/II期试验
这项I/II期试验在32例来那度胺难治性多发性骨髓瘤患者中评估艾沙佐米(3或4 mg)、泊马度胺(4 mg)和地塞米松(40 mg)口服三药方案;31例可评估疗效和毒性。中位随访11.9个月,48%达到部分缓解及以上,20%达到非常好的部分缓解。
要点
- I/II期试验确定艾沙佐米4 mg联合泊马度胺4 mg和地塞米松40 mg为II期推荐剂量。
- 中位随访11.9个月,48%患者达到部分缓解及以上,20%达到非常好的部分缓解。
- 常见不良事件(≥2级)为贫血、中性粒细胞减少、血小板减少和感染,周围神经病变不常见。
核心结论
- 艾沙佐米/泊马度胺/地塞米松是口服联合方案,对复发/难治性多发性骨髓瘤患者耐受良好且有效。
研究设计与样本
- I/II期试验,纳入32例来那度胺难治性多发性骨髓瘤患者,31例可评估疗效和毒性;I期采用3+3设计,II期在推荐II期剂量下额外治疗19例患者。
主要发现
- 剂量水平1(艾沙佐米3 mg)3例中1例出现3级乏力、3级肺部感染、4级中性粒细胞减少和4级血小板减少,均被认为剂量限制性;按3+3设计额外入组3例至剂量水平1,未再出现剂量限制性毒性。
- 剂量水平2(艾沙佐米4 mg)3例中1例出现剂量限制性发热性中性粒细胞减少、中性粒细胞减少和血小板减少(均为4级);剂量水平2扩展额外入组3例,未再出现剂量限制性毒性,确立推荐II期剂量。
- 中位随访11.9个月,48%达到部分缓解及以上,5例(20%)达到非常好的部分缓解,76%达到疾病稳定及以上。
- 最常见不良事件(≥2级)为贫血、中性粒细胞减少、血小板减少和感染;周围神经病变不常见。
关键数值与推荐
- 推荐II期剂量为艾沙佐米4 mg、泊马度胺4 mg和地塞米松40 mg。
- 中位随访11.9个月,48%达到部分缓解及以上,20%达到非常好的部分缓解,76%达到疾病稳定及以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxicity. At dose level 1 (DL1, 3 mg Ixa), 1/3 patients experienced grade 3 fatigue, grade 3 lung infection, grade 4 neutropenia, and grade 4 thrombocytopenia; all were considered dose-limiting. Per 3 + 3 phase I design, an additional three patients were enrolled to DL1, with no further dose-limiting toxicity (DLT). At dose level 2 (DL2, 4 mg Ixa), 1/3 patients had dose-limiting febrile neutropenia, neutropenia, and thrombocytopenia (grade 4 each). DL2 was expanded to enroll three additional patients with no further DLT, establishing the recommended phase II dose (RP2D). In phase II, 19 additional patients were treated at RP2D. With a median follow-up of 11.9 months, 48% achieved ≥ partial response (PR), with 5 patients (20%) achieving very good partial response (VGPR) and 76% experiencing ≥ stable disease. The most common adverse events (≥grade 2) were anemia, neutropenia, thrombocytopenia, and infections. Peripheral neuropathy was infrequent. In summary, Ixa/Pom/Dex is a well-tolerated and effective oral combination therapy for patients with relapsed/refractory MM.
引用
- Krishnan A, Kapoor P, Palmer JM, et al. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2018. PMID: 32082000. doi:10.1038/s41375-018-0038-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。